Doug Burdette

Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.

M. Mingueneau, J. Lyssikatos, T. Bohnert, 2021, Journal of medicinal chemistry.

Seizure reduction in TSC2-mutant mouse model by an mTOR catalytic inhibitor.

D. Curtis, Christopher J. Wilson, A. Rotenberg, 2023, Annals of clinical and translational neurology.